Navigation Links
Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases

MELBOURNE, Australia, Oct. 24, 2011 /PRNewswire/ --

Key Points

  • Mesoblast receives regulatory clearance to begin Phase 2 trial for wet Age-related Macular Degeneration (AMD)
  • Trial will be performed at Singapore National Eye Centre, combining Mesoblast's allogeneic ("off-the-shelf") cells with anti-VEGF agent
  • Wet AMD, the leading cause of blindness in industrialized countries, has different forms in Asia and North America/Europe
  • Anti-VEGF agents are less effective in Asian form of wet AMD
  • Mesoblast's allogeneic cells may be effective for both Asian and North American/European forms of wet AMD
  • Commencing this trial in Singapore is in line with Mesoblast's evolving clinical and manufacturing strategies

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular ("wet") Age-related Macular Degeneration (AMD). Wet AMD causes sudden and severe central vision loss and accounts for approximately 90 percent of all blindness in the elderly. Mesoblast is developing a stem cell therapeutic product for treating various vascular diseases of the eye, including wet AMD and diabetic macular edema (DME).

In North America, the prevalence of wet AMD is estimated to grow to nearly 3 million by 2020, from 1.7 million today, with about 200,000 new cases diagnosed each year. The current standard-of-care for wet AMD in North America is repeated intraocular injections using an anti-vascular endothelial growth factor (anti-VEGF) agent, such as Lucentis and Avastin. However, treatment needs to be maintained long-term since cessation of repeated injections results in rapid disease recurrence and risk of vision loss.

In Asia, wet AMD affects as many as 1.9% of people 65 or older. However, up to 55% of cases of wet AMD in Chinese, Japanese, and Malay populations are caused by Polypoid Choroidal Vasculopathy (PCV), a disorder of eye blood vessel proliferation that is different from the wet form seen in North America and Europe. Anti-VEGF therapy does not result in adequate regression of PCV lesions, and for this reason first line therapy for PCV is photodynamic therapy.

Mesoblast's proprietary adult stem cells may be effective for both forms of wet AMD since they have successfully reduced excessive blood vessel formation and leakiness in several preclinical studies:

1.  Results from a study at the Lions' Eye Institute in Western Australia in 30 rodents with laser-induced excessive blood vessel formation showed that a single intra-ocular injection of human MPC prevented development of leaky blood vessels beyond day 7 after laser-induced damage (eyes treated with MPC had 39% and 32% non-leaky vessels at days 14 and 28, compared with only 7% and 2% non-leaky vessels in the controls at the same time-points, p<0.05).  Moreover, at day 28 only 9% of vessels in eyes treated with a single MPC injection were severely leaking compared with 28% of vessels in control eyes (p<0.05).

2.  Results from a trial at Charles River in Canada in 42 non-human primates with laser-induced excessive blood vessel formation showed that combining a single injection of Mesoblast's allogeneic cells with an injection of the anti-VEGF agent Lucentis resulted in a synergistic, and superior, outcome compared with Lucentis alone in reducing severity of blood vessel leakage within 2 weeks (p<0.05), preventing relapse of severe vessel leakage by days 28-42 (p<0.05), reducing total formation of new blood vessels (p<0.01), and preventing retinal detachment by day 42 (p<0.01).

Mesoblast's randomized, placebo-controlled Phase 2 trial will recruit 18 patients at the Singapore National Eye Centre. The trial will evaluate the safety and effectiveness of a single intraocular injection of Mesoblast's allogeneic Mesenchymal Precursor Cells (MPCs) combined with the anti-VEGF agent Lucentis in newly-diagnosed wet AMD patients. Controls will receive Lucentis alone. The trial will seek to establish if the allogeneic MPC treatment reduces the need for repeated monthly injections of Lucentis whilst improving visual acuity and quality of life.

Mesoblast Chief Executive, Professor Silviu Itescu, said: "Our preclinical results to date suggest that a single injection of Mesoblast's allogeneic cells may be effective for patients with wet AMD, either in combination with an anti-VEGF agent for the form seen in North America/Europe or in combination with photodynamic therapy for the PCV form seen in Asia.  

"Initiating this Phase 2 trial in Singapore will help lay the foundation for us to launch larger trials in parallel for wet AMD in both Asian and non-Asian populations.  

"This signals a clinical strategy by Mesoblast to increasingly target the emerging and very accessible large Asian healthcare markets. This is in line with our broader corporate strategy, including our recent manufacturing agreement with Lonza which provides Mesoblast with exclusive access to Lonza's cell therapy facilities in Singapore for the manufacture of allogeneic products," Professor Itescu added.

About Mesoblast

Mesoblast Limited (ASX: MSB) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).

For further information, please contact:

Julie Meldrum
Corporate Communications
Mesoblast Limited
T: +61 (0)3 9639 6036

SOURCE Mesoblast Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or Off-The-Shelf Stem Cell Treatment for Heart Attacks
2. Coapt Systems Launches FDA Cleared Novielle Voice (TM) for Restoration of Voice Loss
3. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
4. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
5. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
6. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the United States to Utilize Newly FDA-Cleared CARTO(R) 3 Navigation System
7. Zargis Cardioscan Cleared for Sale in Canada
8. Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia
9. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
10. Zargis to Launch FDA-Cleared Lung Sounds Analysis Technology from Stethographics, Inc.
11. Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
Post Your Comments:
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... York , 24. November 2015 /PRNewswire/ ... Avery Breathing Pacemaker Systems, ist erfreut, die ... Clinical Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch ... solutions involving adult stem cell therapies to patients with chronic degenerative medical conditions. ... as a Registered Trademark (RTM). , Organizations are required to hold a registered ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA , ... now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. This ... cutting tools, such as the scalpel and high-speed drill, which can both cause patients ...
(Date:11/24/2015)... Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... explored the different restrictions and variables that determine which patients are or are not ... those patients that have a BMI over 40, are more than 100 pounds overweight, ...
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
Breaking Medicine News(10 mins):